Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absorb, Acino, ACTEMRA, alemtuzumab, Argentina, ARZERRA, Asia, attached, auto, banc, bankruptcy, BART, BBB, benchmark, Biotech, bowel, Brian, Cal, catch, chart, Chugai, circumstance, cladribine, competitor, Consent, conservative, corroborated, CV, declaratory, Deutschland, dispersion, EC, efalizumab, emergence, en, exemplary, EXTAVIA, Facet, FDIC, fifteen, fingolimod, franchise, FSPNo, graph, herewith, hierarchy, highest, highlighted, Hoechst, Hungary, ICC, immaterial, immunotherapy, incidence, inquiry, instability, invalid, invalidation, kroner, lastly, Lehman, lifecycle, LINGO, MAb, mediation, mistakenly, mondoGen, mortgage, MSCRG, nonrecurring, occupancy, override, par, parcel, physical, pivotal, Posner, pre, Progenitor, publish, published, Qualitative, RAPTIVA, recurring, rehearing, reorganization, revocation, revoked, RIXUTAN, roll, Sanofi, sense, slated, speak, split, spot, spring, spun, survey, swap, Tex, tightening, TLGP, tocilizumab, TREANDA, UK, ulcerative, unadjusted, unchanged, unobservable, upgraded, vi, waged, Weston, white, wrote, Zimmer
Removed:
acceleration, accepting, activated, added, Adelman, adhesion, administering, advanced, affiliated, AFFIRM, aggressive, al, ANDA, andRule, animal, announcement, anti, appeal, applicant, applying, argument, arrange, artificially, Authorisation, avoiding, Berlex, bioavailability, bioequivalence, bloodstream, bone, Boston, Brown, Burt, campaign, captioned, cascade, CDAI, choose, close, closely, collection, comparative, comparing, comprise, confirming, conspired, constrain, convey, copy, coupon, Creation, CRIPTO, decedent, declared, deduction, demanded, died, dilution, Dr, Dunn, earning, ENCORE, enhancing, enlarging, entitle, entrepreneurial, essential, evaluated, exchanged, expressed, Faheem, forfeited, formation, formulation, fulfilled, fusion, GAAP, gadolinium, governing, Grill, guarantor, Hasnain, Hillerod, Hybridon, hyperintense, identity, idle, immunomodulatory, indenture, induction, inflating, inhibit, inhibiting, insulation, internet, intervene, intervention, John, Judge, judged, Keller, Kellogg, leader, length, lieu, Lobel, lymphoproliferative, lymphotoxin, Lynch, MAA, Maine, mantle, marrow, McDermott, MDS, Merrill, migrating, migration, misleading, Nassau, negligence, neublastin, neuropathic, NIMO, noncompliance, notifying, observation, observational, observed, opposed, organ, outplacement, page, patchwork, peripheral, personal, personally, phototherapy, physiology, Pillsbury, pioneer, plaque, play, pleaded, power, precursor, predominantly, prevented, priced, principle, proceed, prohibited, promote, promulgated, proper, prospective, purported, purportedly, radioimmunotherapy, randomized, Rastetter, recommend, reconsidered, redeem, redemption, referenced, regenerate, rejection, relied, repatriate, repatriation, representation, rescue, restarted, retreatment, retrospective, role, salary, scan, seal, sensory, SENTINEL, seq, shorten, signaling, solicited, solid, soluble, sought, spanning, specificity, stem, steroid, Street, subordinated, substitute, suffering, thereunder, tissue, TMC, today, tolerated, trained, transfer, transformed, transitional, unrepatriated, unsealed, unspecified, USP, Washington, Winthrop
Filing tables
Filing exhibits
- 10-K Annual report
- 4.4 EX-4.4 Amendment No. 2 to Amended and Restated Rights Agreement Between Biogen Idec and Mellon Investor Services LLC Dated As of January 22, 2009.
- 10.19 EX-10.19 Amendment to Biogen Idec Inc. 2008 Omnibus Equity Plan Dated October 13, 2008
- 10.25 EX-10.25 Amendment to Biogen Idec Inc. 2006 Non-employee Directors Equity Plan Dated October 13, 2008
- 10.30 EX-10.30 Amendment to Biogen Idec Inc. 2005 Omnibus Equity Plan Dated October 13, 2008
- 10.34 EX-10.34 Amendment to Biogen Idec Inc. 2003 Omnibus Equity Plan Dated October 13, 2008
- 10.45 EX-10.45 Amendment to Biogen, Inc. 1985 Non-qualified Stock Option Plan Dated October 13, 2008
- 10.51 EX-10.51 Biogen Idec Inc. Executive Severance Policy - U.S. Executive Vice President, As Amended Effective October 13, 2008.
- 10.52 EX-10.52 Biogen Idec Inc. Executive Severance Policy - International Executive Vice President, As Amended Effective October 13, 2008.
- 10.53 EX-10.53 Biogen Idec Inc. Executive Severance Policy - U.S. Senior Vice President, As Amended Effective October 13, 2008.
- 10.54 EX-10.54 Biogen Idec Inc. Executive Severance Policy - International Senior Vice President, As Amended Effective October 13, 2008.
- 10.59 EX-10.59 Second Amendment to Employment Agreement Between Biogen Idec and James C. Mullen Dated As of December 4, 2008
- 10.61 EX-10.61 Employment Agreement Between Biogen Idec Management Services GMBH and Hans Peter Hasler Dated October 15, 2008.
- 10.63 EX-10.63 First Amendment to Employment Agreement Between Biogen Idec and Cecil B. Pickett Dated As of October 28, 2008
- 10.66 EX-10.66 First Amendment to Employment Agreement Between Biogen Idec and Craig E. Schneier Dated October 8, 2008
- 21.1 EX-21.1 Subsidiaries
- 23.1 EX-23.1 Consent of Pricewaterhousecoopers LLP - an Independent Registered Public Accounting Firm
- 31.1 EX-31.1 Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 EX-31.2 Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32.1 EX-32.1 Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
BIIB similar filings
Filing view
External links
Exhibit 10.63
FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT
THIS AMENDMENT by and between BIOGEN IDEC INC., (the “Company”), and Cecil B. Pickett (the “Executive”), dated as of October 28, 2008.
WHEREAS, the Executive and the Company are parties to an Employment Agreement dated as of June 21, 2006 (the “June 21, 2006 Agreement”); and
WHEREAS, the Executive and the Company desire to amend the June 21, 2006 Agreement as set forth herein.
NOW, THEREFORE, it is hereby agreed as follows:
1. | Attachment D of the June 21, 2006 Agreement is hereby amended and restated in the following manner: |
• | Strike the phrase in the first paragraph “which is not promptly cured after written notice.” | ||
• | Add the following language to the end of the first paragraph: | ||
; or (F) an Involuntary Employment Action as defined in connection with a Corporate Transaction or Change in Control (defined in the 2008 Omnibus Plan). Prior to your termination of employment, you must notify the Chief Legal Counsel or the Head of Human Resources of Biogen Idec in writing of the basis you are terminating your employment in connection with sections (A) through (F) of this paragraph. This written notice must be given to the Company within one year of the circumstances giving rise to you terminating your employment and Biogen Idec will have up to 30 days after the date of your notice to cure such circumstances. |
Signed:
/s/ Cecil B. Pickett | 10/28/08 | |||||
/s/ Craig E. Schneier | 10/30/08 |